Aligos Therapeutics Enters Research Collaboration and Development Agreement with Xiamen Amoytop Biotech

(24/7 MARKET NEWS) – Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported, after Friday’s market close, that it entered into a research collaboration and development agreement with Xiamen Amoytop Biotech for the use of Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.

Aligos is trading at $1.39, up $0.30 (+27.52%), on 1.9M premarket shares traded.

Its 52-week range is $0.8401 to $2.41. Its key inflection points are $1.38 and this morning’s premarket high of $1.89. The move from the $2.25 range to the 87-cent range was on low trading volume, so if the volume picks up it may try to claw some of that back.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist